Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vivos Therapeutics ( (VVOS) ) has provided an update.
On April 17, 2026, Vivos Therapeutics, Inc. disclosed that Nasdaq had notified the company its stockholders’ equity, which was approximately negative $1.55 million as of December 31, 2025, fell below the $2.5 million minimum required for continued listing. The notice does not immediately affect trading of the company’s shares, but triggers a formal compliance process that could ultimately result in delisting if unresolved.
To bolster equity, Vivos has already completed two equity financings in the first quarter of 2026, raising an aggregate $6.8 million through a warrant exercise inducement and a private placement with an existing investor. The company has until June 1, 2026, to submit a remediation plan to Nasdaq and could receive up to an additional 180 days if the plan is accepted, though failure to regain compliance would risk a delisting that the company warns could materially harm its operations and market standing.
The most recent analyst rating on (VVOS) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
The score is weighed down primarily by weak financial performance (ongoing large losses, persistent cash burn, and a materially weakened 2025 balance sheet with higher leverage). Technicals also remain bearish with the stock below key moving averages and negative MACD. The earnings call adds some offsetting upside from the pivot-driven growth narrative and stated path to cash-flow positivity, but near-term liquidity and execution risks remain significant.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc. operates in the healthcare sector and is listed on the Nasdaq Capital Market. The company’s business model depends on access to public equity markets, making continued compliance with Nasdaq listing standards important for its financing flexibility and reputation among investors.
Average Trading Volume: 196,427
Technical Sentiment Signal: Sell
Current Market Cap: $13.62M
See more data about VVOS stock on TipRanks’ Stock Analysis page.